Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 2,154 shares, a growth of ∞ from the June 15th total of 0 shares. Based on an average daily volume of 101,921 shares, the days-to-cover ratio is presently 0.0 days.
Ono Pharmaceutical Trading Down 2.2%
Shares of Ono Pharmaceutical stock opened at $4.87 on Thursday. Ono Pharmaceutical has a 12 month low of $3.52 and a 12 month high of $5.75. The business’s 50-day moving average price is $4.89 and its 200-day moving average price is $4.99.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
Featured Stories
- Five stocks we like better than Ono Pharmaceutical
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
